)
Company Research3 May 2024
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
BioNTech (BNTX) investor relations material
BioNTech Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary3 Nov, 2025
Executive summary
Advanced late-stage oncology pipeline with multiple registrational trials for pumitamig in lung, breast, colorectal, and gastric cancers, aiming for first launches before decade's end and expanded combination approaches.
Expanded clinical programs for mRNA cancer immunotherapies, including FixVac and iNeST, with recent Phase 2 updates guiding development focus and mixed results in melanoma and NSCLC.
Launched a variant-adapted COVID-19 vaccine in major markets for the 2025/2026 season, maintaining commercial leadership and stable market share.
Maintained a strong financial position with €16.7 billion in cash, cash equivalents, and securities, supported by a $1.5 billion upfront payment from the BMS partnership.
Financial highlights
Q3 2025 revenues reached €1,519 million, up from €1,245 million year-over-year, mainly due to $700 million recognized from the BMS collaboration.
Q3 2025 net loss was €29 million, compared to net income of €198 million in Q3 2024, primarily due to a contractual dispute settlement.
R&D expenses for Q3 2025 were €565 million, slightly up year-over-year; nine-month R&D expenses were €1,600 million.
Basic and diluted loss per share for Q3 2025 was €0.12, compared to €0.82 and €0.81 in Q3 2024.
Cash and securities totaled €16.7 billion as of September 30, 2025.
Outlook and guidance
Full-year 2025 revenue guidance raised to €2.6–2.8 billion, up from previous €1.7–2.2 billion, reflecting BMS collaboration revenue.
R&D expense guidance lowered to €2.0–2.2 billion, SG&A to €550–650 million, and capital expenditures to €200–250 million.
No positive net income expected for full-year 2025 as investments continue in oncology transition.
Guidance assumes stable COVID-19 vaccine pricing and market share, with inventory write-downs estimated at 15% of gross profit from vaccine sales in Pfizer's territory.
Pumitamig's expanded pivotal trial strategy
How will cost optimization support growth?
Autogene cevumeran: Next steps after Phase 2?
Pumitamig: Simultaneous ADC combo trials?
R&D guidance cut: What specific programs phased?
mRNA therapy: Why focus on adjuvant CRC/pancreatic?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BioNTech earnings date
R&D Day11 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Additionaly its clinical development will target the treatment of infectious diseases, including prophylactic vaccine approach that includes mRNA. It is also developing various neoantigen-based immunotherapies in collaboration with Pfizer Inc.; other checkpoint molecules; and next-generation antigen receptor T-cell products. The company was formerly known as BioNtech Therapeutics GmbH. BioNTech SE was founded in 2008 and is headquartered in Mainz, Germany.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage